科兴生物制药股份有限公司

Chinese biopharmaceutical company founded on 22 August 1997 and registered in the Mingshui development zone of Zhangqiu district, Jinan, Shandong, listed on the Shanghai STAR Market under code 688136. Develops, manufactures and sells recombinant proteins, multifunctional antibodies and targeted delivery therapies for oncology, autoimmune disease and antiviral treatment, with more than thirty products including recombinant human erythropoietin (Epiao), human interferon alfa-1b (Saironjin), granulocyte colony stimulating factor (Baitexi), the Clostridium butyricum probiotic Changlekang, albumin-bound paclitaxel (Apexelsin) and infliximab. Runs six overseas subsidiaries or offices and has market access and sales in around seventy countries and regions including the European Union, Brazil, the Philippines and Indonesia.